Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20485667
Liu L, et al. (2010) Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS One 5, e10578 20485667
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, Ewing's sarcoma, rhabdomyosarcoma
Relevant cell lines - cell types - tissues:  Rh1 (bone cell), Rh30 (muscle cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 mTOR (human) inhibit treatment-induced increase
okadaic_acid IGF-1 no effect upon treatment-induced increase
PD98059 IGF-1 inhibit treatment-induced increase
okadaic_acid, rapamycin IGF-1 no effect upon treatment-induced increase
okadaic_acid increase slight increase
rapamycin no change compared to control
PPP2CA (human) decrease dominant negative PP2A increases

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, Ewing's sarcoma, rhabdomyosarcoma
Relevant cell lines - cell types - tissues:  Rh1 (bone cell), Rh30 (muscle cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 mTOR (human) inhibit treatment-induced increase
okadaic_acid IGF-1 no effect upon treatment-induced increase
PD98059 IGF-1 inhibit treatment-induced increase
okadaic_acid, rapamycin IGF-1 no effect upon treatment-induced increase
okadaic_acid increase slight increase
rapamycin no change compared to control
PPP2CA (human) decrease dominant negative PP2A increases

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, Ewing's sarcoma, rhabdomyosarcoma
Relevant cell lines - cell types - tissues:  Rh1 (bone cell), Rh30 (muscle cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 mTOR (human) inhibit treatment-induced increase
okadaic_acid IGF-1 no effect upon treatment-induced increase
PD98059 IGF-1 inhibit treatment-induced increase
okadaic_acid, rapamycin IGF-1 no effect upon treatment-induced increase
okadaic_acid increase slight increase
rapamycin no change compared to control
PPP2CA (human) decrease dominant negative PP2A increases

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, Ewing's sarcoma, rhabdomyosarcoma
Relevant cell lines - cell types - tissues:  Rh1 (bone cell), Rh30 (muscle cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
rapamycin IGF-1 mTOR (human) inhibit treatment-induced increase
okadaic_acid IGF-1 no effect upon treatment-induced increase
PD98059 IGF-1 inhibit treatment-induced increase
okadaic_acid, rapamycin IGF-1 no effect upon treatment-induced increase
okadaic_acid increase slight increase
rapamycin no change compared to control
PPP2CA (human) decrease dominant negative PP2A increases

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer, Ewing's sarcoma, rhabdomyosarcoma
Relevant cell lines - cell types - tissues:  Rh1 (bone cell), Rh30 (muscle cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGF-1 increase
mTOR (human) increase mTOR shRNA decreases